COLLABORATE El Meu Clínic .This link opens in a new tab.
COLLABORATE El Meu Clínic .This link opens in a new tab.
Make a donation
Navigation thread
Navigation thread
Translational genomics and targeted therapies in solid tumours
Make a donation

Featured projects

  • Tratamiento del cáncer de mama triple negativo avanzado o metastásico con terapia adoptiva de linfocitos infiltrantes de tumores PD1+ (ensayo TILS001)

    Principal investigator: Aleix Prat Aparicio.
    Funder: Instituto de Salud Carlos III (ISCIII).
    Code: ICI24/00062.
    Duration: 01/01/2025 - 01/01/2029

  • Phase Ia/Ib Clinical Trial of ONA-255, a first-in-class ADC for refractory HR+ HER2- breast cancer patients

    Principal investigator: María Vidal.
    Funder: Agencia Estatal de Investigacion (AEI).
    Code: CPP2024-011305.
    Duration: 01/01/2025 - 01/01/2028

  • Developing a new diagnostic test for personalised treatment of triple negative breast cancer

    Principal investigator: Aleix Prat Aparicio.
    Funder: Agencia Estatal de Investigacion (AEI).
    Code: CPP2024-011794.
    Duration: 01/01/2025 - 01/01/2028

  • Discovery and validation of therapeutic targets for the development of an antibody-drug conjugare to overcome resistance to current treatments in metastatic breast cancer

    Principal investigator: Aleix Prat Aparicio.
    Funder: Fundacion Cris contra el cancer.
    Code: Dame5mas.
    Duration: 01/01/2025 - 01/01/2028

  • AECC-IDIBAPS Excellence Program: Pioneering Strategies to Maximize Immunotherapy Efficacy in Cancer

    Principal investigator: Aleix Prat Aparicio.
    Funder: Fundacion Cientifica de la Asociacion Espanola contra el Cancer.
    Code: Excellence Program AECC 2024.
    Duration: 01/01/2025 - 01/01/2029

  • Mapping metastasis plasticity (METMAP)

    Principal investigator: Aleix Prat Aparicio, Roger Gomis.
    Funder: La Caixa Foundation.
    Code: HR24-00279.
    Duration: 01/01/2025 - 01/01/2028

  • Genomic-Based Biomarkers for Predicting Ribociclib Response in Early-Stage Hormone Receptor-Positive and HER2-Negative Breast Cancer (RIBOLARIS-PREDICT)

    Principal investigator: Aleix Prat Aparicio.
    Funder: Breast Cancer Research Foundation.
    Code: BCRF-24-198.
    Duration: 01/01/2024 - 01/01/2026

  • DEFINITIVE. Diagnostic HER2DX-guided treatment for patients with early-stage HER2-positive breast cancer

    Principal investigator: Aleix Prat Aparicio.
    Funder: European Comission.
    Code: 101136953.
    Duration: 01/01/2023 - 01/01/2028

  • CRIS Research Excellence Programmes 2021. Dissecting and overcoming mechanisms of resistance to CDK4/6 inhibition in advanced hormone receptor-positive/HER2-Negative HER2-Enriched breast cancer

    Principal investigator: Aleix Prat Aparicio.
    Funder: FUNDACION CRIS DE INVESTIGACION PARA VENCER EL CANCER.
    Code: PR_EX_2021-14.
    Duration: 01/07/2022 - 30/06/2027

Major founders

The research of this group can be carried out thanks to the funders.

Contributors

Donations that make possible the research of this group.